Tazeen Ahmad
Stock Analyst at B of A Securities
(3.24)
# 1,015
Out of 4,667 analysts
186
Total ratings
46.15%
Success rate
1.57%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEPG PepGen | Maintains: Neutral | $10 → $6 | $4.25 | +41.18% | 2 | Nov 18, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $61 → $47 | $27.01 | +74.01% | 6 | Nov 6, 2024 | |
| INCY Incyte | Upgrades: Buy | $68 → $90 | $70.29 | +28.04% | 5 | Oct 30, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $13 → $15 | $9.49 | +58.06% | 3 | Oct 17, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $307 → $314 | $249.20 | +26.00% | 2 | Oct 14, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Neutral | $48 → $52 | $58.96 | -11.80% | 7 | Oct 14, 2024 | |
| SAGE Sage Therapeutics | Maintains: Underperform | $11 → $6 | $5.00 | +20.00% | 14 | Oct 9, 2024 | |
| PRTA Prothena Corporation | Maintains: Neutral | $33 → $31 | $14.32 | +116.48% | 4 | Oct 1, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $175 → $191 | $123.75 | +54.34% | 8 | Sep 23, 2024 | |
| BNTX BioNTech SE | Maintains: Buy | $125 → $150 | $103.85 | +44.44% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $3.05 | -34.43% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $29 | $24.01 | +20.78% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $76 | $43.67 | +74.03% | 4 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $535 → $607 | $590.80 | +2.74% | 3 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $25 → $32 | $42.43 | -24.58% | 15 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $166 → $213 | $110.01 | +93.62% | 21 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $46.62 | +63.02% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $22 | $15.84 | +38.89% | 13 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.61 | +359.77% | 1 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $2.65 | +428.30% | 2 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $5.30 | +88.68% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $2.10 | +185.71% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $8.70 | +72.51% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $0.5 | $1.05 | -52.38% | 1 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $20.60 | -46.60% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $7.30 | +36.99% | 11 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $33 | $8.20 | +302.44% | 2 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $1.98 | +1.01% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $0.94 | +537.42% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $9.10 | +64.93% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $73.53 | -18.40% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $23 | $0.37 | +5,981.08% | 2 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $2.07 | +672.95% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $24.41 | +350.63% | 1 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $8.10 | +430.86% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $193.44 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $60 | $0.50 | +11,924.05% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $1.19 | +656.30% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $17.37 | +176.34% | 6 | Oct 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $102 | $124.71 | -18.21% | 2 | May 1, 2018 |
PepGen
Nov 18, 2024
Maintains: Neutral
Price Target: $10 → $6
Current: $4.25
Upside: +41.18%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $61 → $47
Current: $27.01
Upside: +74.01%
Incyte
Oct 30, 2024
Upgrades: Buy
Price Target: $68 → $90
Current: $70.29
Upside: +28.04%
Amicus Therapeutics
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $9.49
Upside: +58.06%
Alnylam Pharmaceuticals
Oct 14, 2024
Maintains: Buy
Price Target: $307 → $314
Current: $249.20
Upside: +26.00%
Rhythm Pharmaceuticals
Oct 14, 2024
Maintains: Neutral
Price Target: $48 → $52
Current: $58.96
Upside: -11.80%
Sage Therapeutics
Oct 9, 2024
Maintains: Underperform
Price Target: $11 → $6
Current: $5.00
Upside: +20.00%
Prothena Corporation
Oct 1, 2024
Maintains: Neutral
Price Target: $33 → $31
Current: $14.32
Upside: +116.48%
Ascendis Pharma
Sep 23, 2024
Maintains: Buy
Price Target: $175 → $191
Current: $123.75
Upside: +54.34%
BioNTech SE
Sep 16, 2024
Maintains: Buy
Price Target: $125 → $150
Current: $103.85
Upside: +44.44%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $3.05
Upside: -34.43%
Sep 4, 2024
Maintains: Buy
Price Target: $25 → $29
Current: $24.01
Upside: +20.78%
Jun 25, 2024
Maintains: Buy
Price Target: $76
Current: $43.67
Upside: +74.03%
Jun 24, 2024
Reiterates: Buy
Price Target: $535 → $607
Current: $590.80
Upside: +2.74%
Jun 21, 2024
Maintains: Underperform
Price Target: $25 → $32
Current: $42.43
Upside: -24.58%
Jun 21, 2024
Maintains: Buy
Price Target: $166 → $213
Current: $110.01
Upside: +93.62%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $46.62
Upside: +63.02%
May 10, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $15.84
Upside: +38.89%
May 8, 2024
Initiates: Buy
Price Target: $12
Current: $2.61
Upside: +359.77%
Apr 9, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $2.65
Upside: +428.30%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $5.30
Upside: +88.68%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $2.10
Upside: +185.71%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $8.70
Upside: +72.51%
Dec 14, 2023
Downgrades: Underperform
Price Target: $7 → $0.5
Current: $1.05
Upside: -52.38%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $20.60
Upside: -46.60%
Jul 13, 2023
Upgrades: Buy
Price Target: $10
Current: $7.30
Upside: +36.99%
Jun 8, 2023
Maintains: Buy
Price Target: $28 → $33
Current: $8.20
Upside: +302.44%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $1.98
Upside: +1.01%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $0.94
Upside: +537.42%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $9.10
Upside: +64.93%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $73.53
Upside: -18.40%
May 27, 2022
Downgrades: Underperform
Price Target: $23
Current: $0.37
Upside: +5,981.08%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $2.07
Upside: +672.95%
Sep 9, 2021
Initiates: Buy
Price Target: $110
Current: $24.41
Upside: +350.63%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $8.10
Upside: +430.86%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $193.44
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $66 → $60
Current: $0.50
Upside: +11,924.05%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $1.19
Upside: +656.30%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $17.37
Upside: +176.34%
May 1, 2018
Maintains: Buy
Price Target: $101 → $102
Current: $124.71
Upside: -18.21%